BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23272083)

  • 1. Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT(®)-Lung Test.
    Macdonald IK; Murray A; Healey GF; Parsy-Kowalska CB; Allen J; McElveen J; Robertson C; Sewell HF; Chapman CJ; Robertson JF
    PLoS One; 2012; 7(12):e51002. PubMed ID: 23272083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and validation of a high throughput system for discovery of antigens for autoantibody detection.
    Macdonald IK; Allen J; Murray A; Parsy-Kowalska CB; Healey GF; Chapman CJ; Sewell HF; Robertson JF
    PLoS One; 2012; 7(7):e40759. PubMed ID: 22815807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice.
    Jett JR; Peek LJ; Fredericks L; Jewell W; Pingleton WW; Robertson JF
    Lung Cancer; 2014 Jan; 83(1):51-5. PubMed ID: 24268382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
    Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial.
    Sullivan FM; Farmer E; Mair FS; Treweek S; Kendrick D; Jackson C; Robertson C; Briggs A; McCowan C; Bedford L; Young B; Vedhara K; Gallant S; Littleford R; Robertson J; Sewell H; Dorward A; Sarvesvaran J; Schembri S
    BMC Cancer; 2017 Mar; 17(1):187. PubMed ID: 28284200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort.
    Borg M; Wen SWC; Nederby L; Hansen TF; Jakobsen A; Andersen RF; Weinreich UM; Hilberg O
    Lung Cancer; 2021 Aug; 158():85-90. PubMed ID: 34130044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.
    Chapman CJ; Healey GF; Murray A; Boyle P; Robertson C; Peek LJ; Allen J; Thorpe AJ; Hamilton-Fairley G; Parsy-Kowalska CB; MacDonald IK; Jewell W; Maddison P; Robertson JF
    Tumour Biol; 2012 Oct; 33(5):1319-26. PubMed ID: 22492236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can autoantibody tests enhance lung cancer screening?-an evaluation of EarlyCDT
    González Maldonado S; Johnson T; Motsch E; Delorme S; Kaaks R
    Transl Lung Cancer Res; 2021 Jan; 10(1):233-242. PubMed ID: 33569307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts.
    Wu WY; Haider Z; Feng X; Heath AK; Tjønneland A; Agudo A; Masala G; Robbins HA; Huerta JM; Guevara M; Schulze MB; Rodriguez-Barranco M; Vineis P; Tumino R; Kaaks R; Fortner RT; Sieri S; Panico S; Nøst TH; Sandanger TM; Braaten T; Johansson M; Melin B; Johansson M
    Int J Cancer; 2023 May; 152(9):2002-2010. PubMed ID: 36305647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal stratification of autoantibody levels in serum samples and its application to the early detection of lung cancer.
    Healey GF; Lam S; Boyle P; Hamilton-Fairley G; Peek LJ; Robertson JF
    J Thorac Dis; 2013 Oct; 5(5):618-25. PubMed ID: 24255775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening.
    Bigbee WL; Gopalakrishnan V; Weissfeld JL; Wilson DO; Dacic S; Lokshin AE; Siegfried JM
    J Thorac Oncol; 2012 Apr; 7(4):698-708. PubMed ID: 22425918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.
    Sullivan FM; Mair FS; Anderson W; Armory P; Briggs A; Chew C; Dorward A; Haughney J; Hogarth F; Kendrick D; Littleford R; McConnachie A; McCowan C; McMeekin N; Patel M; Rauchhaus P; Ritchie L; Robertson C; Robertson J; Robles-Zurita J; Sarvesvaran J; Sewell H; Sproule M; Taylor T; Tello A; Treweek S; Vedhara K; Schembri S;
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32732334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules.
    Wang J; Shivakumar S; Barker K; Tang Y; Wallstrom G; Park JG; Tsay JC; Pass HI; Rom WN; LaBaer J; Qiu J
    J Thorac Oncol; 2016 Mar; 11(3):334-45. PubMed ID: 26896032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of a new autoantibody test added to Computed Tomography (CT) compared to CT surveillance alone in the diagnosis of lung cancer amongst patients with indeterminate pulmonary nodules.
    Sutton AJ; Sagoo GS; Jackson L; Fisher M; Hamilton-Fairley G; Murray A; Hill A
    PLoS One; 2020; 15(9):e0237492. PubMed ID: 32877432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of a plasma biomarker panel for discerning clinical significance of indeterminate pulmonary nodules.
    Daly S; Rinewalt D; Fhied C; Basu S; Mahon B; Liptay MJ; Hong E; Chmielewski G; Yoder MA; Shah PN; Edell ES; Maldonado F; Bungum AO; Borgia JA
    J Thorac Oncol; 2013 Jan; 8(1):31-6. PubMed ID: 23201823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and blood based biomarkers for lung cancer screening: a systematic review.
    Chu GCW; Lazare K; Sullivan F
    BMC Cancer; 2018 Feb; 18(1):181. PubMed ID: 29439651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer.
    Ostroff RM; Bigbee WL; Franklin W; Gold L; Mehan M; Miller YE; Pass HI; Rom WN; Siegfried JM; Stewart A; Walker JJ; Weissfeld JL; Williams S; Zichi D; Brody EN
    PLoS One; 2010 Dec; 5(12):e15003. PubMed ID: 21170350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovering Panel of Autoantibodies for Early Detection of Lung Cancer Based on Focused Protein Array.
    Jiang D; Zhang X; Liu M; Wang Y; Wang T; Pei L; Wang P; Ye H; Shi J; Song C; Wang K; Wang X; Dai L; Zhang J
    Front Immunol; 2021; 12():658922. PubMed ID: 33968062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early detection of lung cancer by using an autoantibody panel in Chinese population.
    Ren S; Zhang S; Jiang T; He Y; Ma Z; Cai H; Xu X; Li Y; Cai W; Zhou J; Liu X; Hu X; Zhang J; Yu H; Zhou C; Hirsch FR
    Oncoimmunology; 2018; 7(2):e1384108. PubMed ID: 29308305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.